Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 384

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

Open access
Taskesen, Erdogan, Bullinger, Lars, Corbacioglu, Andrea, Sanders, Mathijs A., Erpelinck, Claudia A. J., Wouters, Bas J., van der Poel-van de Luytgaarde, Sonja C., Damm, Frederik, Krauter, Jürgen, Ganser, Arnold, Schlenk, Richard F., Löwenberg, Bob, Delwel, Ruud, Döhner, Hartmut, Valk, Peter J. M., Döhner, Konstanze·2011·Blood
DOI 10.1182/blood-2010-09-307280
Open this paper in CoChat — free account

Abstract

We evaluated concurrent gene mutations, clinical outcome, and gene expression signatures of CCAAT/enhancer binding protein alpha (CEBPA) double mutations (CEBPAdm) versus single mutations (CEBPAsm) in 1182 cytogenetically normal acute myeloid leukemia (AML) patients (16-60 years of age). We identified 151 (12.8%) patients with CEBPA mutations (91 CEBPAdm and 60 CEBPAsm). The incidence of germline mutations was 7% (5 of 71), including 3 C-terminal mutations. CEBPAdm patients had a lower frequency of concurrent mutations than CEBPAsm patients (P < .0001). Both, groups were associated with a favorable outcome compared with CEBPAwt (5-year overall survival [OS] 63% and 56% vs 39%; P < .0001 and P = .05, respectively). However, in multivariable analysis only CEBPAdm was a prognostic factor for favorable OS outcome (hazard ratio [HR] 0.36, P < .0001; event-free survival, HR 0.41, P < .0001; relapse-free survival, HR 0.55, P = .001). Outcome in CEBPAsm is dominated by concurrent NPM1 and/or FLT3 internal tandem duplication mutations. Unsupervised and supervised GEP analyses showed that CEBPAdm AML (n = 42), but not CEBPAsm AML (n = 18), expressed a unique gene signature. A 25-probe set prediction signature for CEBPAdm AML showed 100% sensitivity and specificity. Based on these findings, we propose that CEBPAdm should be clearly defined from CEBPAsm AML and considered as a separate entity in the classification of AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-09-307280

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 384

Metadata

Authors
Taskesen, E., Bullinger, L., Corbacioglu, A., Sanders, M. A., Erpelinck, C. A. J., Wouters, B. J., van der Poel-van de Luytgaarde, S. C., Damm, F., Krauter, J., Ganser, A., Schlenk, R. F., Löwenberg, B., Delwel, R., Döhner, H., Valk, P. J. M., & Döhner, K.
Venue
Blood
Publisher
American Society of Hematology
Published
2011-02-24
Volume
117
Issue
8
Pages
2469-2475
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2010-09-307280
OpenAlex
W2086915316
Cited by
384
References
41
FWCI
14.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. https://app.cochat.ai/papers/10.1182/blood-2010-09-307280
The paper
Taskesen, E., Bullinger, L., Corbacioglu, A., Sanders, M. A., Erpelinck, C. A. J., Wouters, B. J., van der Poel-van de Luytgaarde, S. C., Damm, F., Krauter, J., Ganser, A., Schlenk, R. F., Löwenberg, B., Delwel, R., Döhner, H., Valk, P. J. M., & Döhner, K. (2011). Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. https://doi.org/10.1182/blood-2010-09-307280

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.